Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

被引：31
|
作者：
LaCasce, Ann S. [1 ]
Bociek, R. Gregory [2 ]
Sawas, Ahmed [3 ]
Caimi, Paolo [4 ]
Agura, Edward [5 ]
Matous, Jeffrey [6 ]
Ansell, Stephen M. [7 ]
Crosswell, Howland E. [8 ]
Islas-Ohlmayer, Miguel [9 ]
Behler, Caroline [10 ]
Cheung, Eric [11 ]
Forero-Torres, Andres [12 ,13 ,15 ]
Vose, Julie [2 ]
O'Connor, Owen A. [3 ]
Josephson, Neil [13 ,15 ]
Wang, Yinghui [13 ]
Advani, Ranjana [14 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Columbia Univ, Med Ctr, New York, NY USA
[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[5] Charles A Sammons Canc Ctr, Dallas, TX USA
[6] Colorado Blood Canc Inst, Denver, CO USA
[7] Mayo Clin, Rochester, MN USA
[8] St Francis Hosp, Greenville, SC USA
[9] Jewish Hosp Mercy Hlth, Cincinnati, OH USA
[10] Pacific Hematol Oncol Associates, San Francisco, CA USA
[11] Oncol Inst Hope & Innovat, Whittier, CA USA
[12] Univ Alabama Birmingham, Birmingham, AL USA
[13] Seattle Genet Inc, Bothell, WA USA
[14] Stanford Canc Inst, Stanford, CA USA
[15] Zymeworks Biopharmaceut Inc, Bothell, WA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期
关键词：
Hodgkin lymphoma; first salvage therapy; autologous stem cell transplantation; brentuximab vedotin; bendamustine; STEM-CELL TRANSPLANTATION; PHASE-II; CHEMOTHERAPY;
D O I：
10.1111/bjh.16499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E86 / E90
页数：5
相关论文
共 50 条
  • [41] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
    Kaleka, Guneet
    Moskoff, Benjamin
    Zafar, Aneeqa
    Esteghamat, Naseem S.
    Abedi, Mehrdad
    Socola, Francisco Andres
    Hoeg, Rasmus T.
    Tuscano, Joseph M.
    BLOOD, 2024, 144 : 6318 - 6319
  • [42] PET ADAPTED DOSE ESCALATION OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSE/REFRACTORY HODGKIN LYMPHOMA
    Chen, R.
    Palmer, J.
    Herrera, A.
    Chen, B.
    Tsai, N.
    Armenian, S.
    Kennedy, N.
    Cai, J. -L.
    Nademanee, A.
    Mei, M.
    Kwak, L.
    Rosen, S.
    Forman, S.
    HAEMATOLOGICA, 2016, 101 : 46 - 46
  • [43] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [44] Efficacy of Brentuximab Vedotin and Bendamustine Combination in Relapsed/Refractory Hodgkin Lymphoma: Experience from a Tertiary Care Hospital
    Alrajhi, Abdullah M.
    Aljalali, Razan A.
    Alghazi, Lara H.
    Asiri, Ibrahim
    Alnakhli, Adel
    Alnajjar, Fouad H.
    Alshehry, Nawal F.
    Motabi, Ibraheem H.
    Alnoamani, Mohammed S.
    Marei, Mohammed A.
    Alfayez, Mansour
    Tailor, Imran K.
    BLOOD, 2021, 138
  • [45] BRENTUXIMAB VEDOTIN FOLLOWED BY BENDAMUSTINE SUPERCHARGE FOR REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MATURE RESULTS OF A MONOCENTRIC PROSPECTIVE TRIAL
    Della Pepa, R.
    Picardi, M.
    Pugliese, N.
    Giordano, C.
    Leone, A.
    Muriano, F.
    Pane, F.
    HAEMATOLOGICA, 2020, 105 : S101 - S102
  • [46] Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma
    Garciaz, Sylvain
    Coso, Diane
    Peyrade, Frederic
    Fuerst, Sabine
    Duran, Segolene
    Chetaille, Bruno
    Brenot-Rossi, Isabelle
    Devillier, Raynier
    Granata, Angela
    Blaise, Didier
    Bouabdallah, Reda
    HEMATOLOGICAL ONCOLOGY, 2014, 32 (04) : 187 - 191
  • [47] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Maerevoet, Marie
    Meuleman, Nathalie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S250 - S250
  • [48] A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
    Cao, Zhi-Gang
    Zhou, Hong-Wei
    Peng, Chao-Jin
    Liu, Mo
    Du, Yu
    Yang, Qing-Ming
    CHINESE JOURNAL OF CANCER, 2013, 32 (09) : 520 - 523
  • [49] EXPERIENCE WITH BRENTUXIMAB VEDOTIN IN RELAPSED/ REFRACTORY HODGKIN LYMPHOMA IN THE PROVINCE OF CADIZ
    Verdugo Cabeza De Vaca, Ma V.
    Cuellar Garcia, C.
    Romero Gonzalez, Ma dM
    Fernandez Valle, Ma dC
    Berruezo Salazar, Ma J.
    Paz Coll, A.
    Garzon Lopez, S.
    HAEMATOLOGICA, 2015, 100 : 174 - 174
  • [50] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
    Angelopoulou, Maria K.
    Vassilakopoulos, Theodoros P.
    Batsis, Ioannis
    Sakellari, Ioanna
    Gkirkas, Konstantinos
    Pappa, Vasiliki
    Giannoulia, Panagiota
    Apostolidis, Ioannis
    Apostolopoulos, Christos
    Roussou, Paraskevi
    Panayiotidis, Panayiotis
    Dimou, Maria
    Kyrtsonis, Marie-Christine
    Palassopoulou, Maria
    Vassilopoulos, Georgios
    Moschogiannis, Maria
    Kalpadakis, Christina
    Margaritis, Dimitrios
    Spyridonidis, Alexander
    Michalis, Eurydiki
    Anargyrou, Konstantinos
    Repousis, Panagiotis
    Hatzimichael, Eleutheria
    Bousiou, Zoi
    Poulakidas, Elias
    Grentzelias, Dimitrios
    Harhalakis, Nikolaos
    Pangalis, Gerassimos A.
    Anagnostopoulos, Achilles
    Tsirigotis, Panagiotis
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 174 - 181
12345